Biocon Biologics and Yoshindo expand access to Ustekinumab Biosimilar in Japan

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that its commercial partner in Japan, Yoshindo Inc., has launched Ustekinumab BS Subcutaneous Injection [YD], a biosimilar to the reference product Stelara® (ustekinumab). The biosimilar ustekinumab, developed and manufactured by Biocon Biologics, is commercialized and marketed in Japan by Yoshindo Inc.

Ustekinumab, a monoclonal antibody, is approved for the treatment of psoriasis vulgaris and psoriatic arthritis (PsA).

In April 2024, the Company entered into a settlement and licensing agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (collectively known as Janssen) to commercialize Ustekinumab in Japan upon regulatory approval. Biocon Biologics' biosimilar Ustekinumab BS Subcutaneous Injection [YD] was approved by the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan in December 2024.

Biocon Biologics has already launched Ustekinumab in the United States and Europe in February 2025 to help patients manage their chronic conditions.

Shares of Biocon Limited was last trading in BSE at Rs. 332.75 as compared to the previous close of Rs. 341.55. The total number of shares traded during the day was 53834 in over 1161 trades.

The stock hit an intraday high of Rs. 342.95 and intraday low of 331.55. The net turnover during the day was Rs. 18124967.00.

Source : Equity Bulls

Keywords

Biocon INE376G01013 Biotechnology BioconBiologics CommercialPartner Yoshido Japan Ustekinumab